DE69332469T2 - Metallkomplexe von wasserlöslichen texaphyrinen - Google Patents

Metallkomplexe von wasserlöslichen texaphyrinen

Info

Publication number
DE69332469T2
DE69332469T2 DE69332469T DE69332469T DE69332469T2 DE 69332469 T2 DE69332469 T2 DE 69332469T2 DE 69332469 T DE69332469 T DE 69332469T DE 69332469 T DE69332469 T DE 69332469T DE 69332469 T2 DE69332469 T2 DE 69332469T2
Authority
DE
Germany
Prior art keywords
soluble
water
metal complexes
texaphyrines
texaphyrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332469T
Other languages
English (en)
Other versions
DE69332469D1 (de
Inventor
L Sessler
W Hemmi
D Mody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of DE69332469D1 publication Critical patent/DE69332469D1/de
Publication of DE69332469T2 publication Critical patent/DE69332469T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
DE69332469T 1992-01-21 1993-01-07 Metallkomplexe von wasserlöslichen texaphyrinen Expired - Fee Related DE69332469T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/822,964 US5252720A (en) 1989-03-06 1992-01-21 Metal complexes of water soluble texaphyrins
PCT/US1993/000107 WO1993014093A1 (en) 1992-01-21 1993-01-07 Metal complexes of water soluble texaphyrins

Publications (2)

Publication Number Publication Date
DE69332469D1 DE69332469D1 (de) 2002-12-12
DE69332469T2 true DE69332469T2 (de) 2003-07-10

Family

ID=25237423

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332469T Expired - Fee Related DE69332469T2 (de) 1992-01-21 1993-01-07 Metallkomplexe von wasserlöslichen texaphyrinen

Country Status (15)

Country Link
US (9) US5252720A (de)
EP (1) EP0623134B1 (de)
JP (1) JP3530529B2 (de)
KR (1) KR100286963B1 (de)
AT (1) ATE227291T1 (de)
AU (1) AU664877B2 (de)
CA (1) CA2127530C (de)
DE (1) DE69332469T2 (de)
DK (1) DK0623134T3 (de)
ES (1) ES2185627T3 (de)
FI (1) FI107157B (de)
NO (1) NO301828B1 (de)
NZ (1) NZ246795A (de)
PT (1) PT623134E (de)
WO (1) WO1993014093A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5457195A (en) * 1989-12-21 1995-10-10 Board Of Regents, The University Of Texas System Sapphyrin derivatives and conjugates
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5798491A (en) * 1993-06-09 1998-08-25 Board Of Regents, The University Of Texas System Multi-mechanistic chemical cleavage using certain metal complexes
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
EP0841965B1 (de) * 1994-03-21 2002-04-10 Dusa Pharmaceuticals, Inc. Pflaster und steuereinrichtung für photodynamische therapie von dermalen verletzungen
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
AU733805C (en) * 1994-06-13 2001-12-13 Unilever Plc Bleach activation
EP0765381B1 (de) * 1994-06-13 1999-08-11 Unilever N.V. Bleichaktivierung
US5530122A (en) * 1994-08-23 1996-06-25 Pharmacyclics, Inc. Method of isolating texaphyrins
US5837866A (en) * 1994-09-21 1998-11-17 Board Of Regents, The University Of Texas Phosphoramidite derivatives of macrocycles
US5633354A (en) * 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US6095147A (en) * 1994-12-01 2000-08-01 The Regents Of The University Of California Method for photo-altering a biological system to improve biological effect
US5703230A (en) * 1994-12-02 1997-12-30 University Of British Columbia Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
BR9610240A (pt) * 1995-08-17 1999-06-29 Monsanto Co Métodos de análise de imagem para diagnóstico utilizando complexos de metal de ligantes macrociclicos que contém nitrogênio
WO1997006830A1 (en) 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
JP2001520637A (ja) 1995-09-06 2001-10-30 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 二光子アップコンバーティング色素および応用
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US5955586A (en) * 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
WO1997035617A1 (en) * 1996-03-26 1997-10-02 Pharmacyclics, Inc. Use of a texaphyrin in photodynamic therapy of pigment-related lesions
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6022959A (en) * 1996-08-20 2000-02-08 Pharmacyclics, Inc. Nucleic acids internally-derivatized with a texaphyrin metal complex and uses thereof
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
WO2000000204A1 (en) 1997-02-14 2000-01-06 Miravant Pharmaceuticals, Inc. Indium photosensitizers for pdt
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
ATE383364T1 (de) 1999-05-27 2008-01-15 Monsanto Co Biomaterialien, modifiziert mit superoxid- dismutase imitatoren
CN1358171A (zh) * 1999-06-08 2002-07-10 拉卓拉药物公司 包含氨基氧基的化合价平台分子
EP1267935A2 (de) * 2000-01-12 2003-01-02 Light Sciences Corporation Behandlung von augenerkrankungen
US6949620B2 (en) * 2000-01-26 2005-09-27 Japan Science And Technology Corporation Polymeric micellar structure
CN1434726A (zh) * 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
AU2001290580A1 (en) * 2000-08-30 2002-03-13 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
WO2002100478A2 (en) * 2001-06-11 2002-12-19 Cavalier Discovery Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
AU2002315208A1 (en) * 2001-06-12 2002-12-23 University Of Florida Method and device for producing near-infrared radiation
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
WO2003072581A1 (en) 2002-02-26 2003-09-04 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
AU2003298725A1 (en) * 2002-12-04 2004-06-23 Pharmacyclics, Inc. Preparation of metallotexaphyrins
EP1581212A4 (de) * 2002-12-06 2008-11-05 Alcon Inc Superoxid-dismutase-imitationen zur behandlung von augenstörungen und erkrankungen
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20050118102A1 (en) * 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20050196466A1 (en) * 2004-03-02 2005-09-08 Pharmacyclics, Inc. Process for inhibiting cell proliferation
EP1765163A1 (de) * 2004-05-20 2007-03-28 Pharmacyclics, Inc. Verfahren zur verbesserung der visualisierung von atherosklerotischem plaque
US20060171845A1 (en) * 2005-01-31 2006-08-03 Dakota Technologies, Inc. Sensors for measuring analytes
WO2006080022A2 (en) * 2005-01-31 2006-08-03 Yeda Research And Development Co. Ltd. Mri contrast agents for diagnosis and prognosis of tumors
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
WO2006116021A2 (en) * 2005-04-22 2006-11-02 Intematix Corporation Mri technique based on electron spin resonance and endohedral contrast agent
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
US20090197853A1 (en) * 2005-11-16 2009-08-06 Pharmacyclics, Inc. Methods and compositions of treating cancer
US7528125B2 (en) * 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
WO2008020113A1 (en) * 2006-08-18 2008-02-21 Abacus Diagnostica Oy Luminescent lanthanide labelling reagents and their use
US8133474B2 (en) * 2006-09-15 2012-03-13 Massachusetts Institute Of Technology Sensors for fluorescence and magnetic resonance imaging
WO2009003173A1 (en) * 2007-06-27 2008-12-31 The General Hospital Corporation Method and apparatus for optical inhibition of photodymanic therapy
WO2009006075A2 (en) * 2007-06-29 2009-01-08 Board Of Regents, The University Of Texas System Functionalized expanded porphyrins
CZ300197B6 (cs) * 2007-08-31 2009-03-11 Vysoká škola chemicko-technologická v Praze Použití multimodálních systému pro prípravu prípravku k lécbe a diagnostikování nádorových onemocnení
CA2706420C (en) * 2007-12-07 2016-04-19 Prana Biotechnology Ltd Organometallic ligands for therapy and diagnosis
US8835104B2 (en) * 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US8802074B2 (en) 2008-11-26 2014-08-12 Board Of Regents, The University Of Texas System Polymers functionalized with ion-specific recognition elements
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
US20110272273A1 (en) * 2010-05-07 2011-11-10 Molycorp Minerals, Llc Lanthanide-mediated photochemical water splitting process for hydrogen and oxygen generation
US9402866B2 (en) 2011-04-07 2016-08-02 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
BR112014022228A2 (pt) 2012-03-08 2017-07-11 Halozyme Inc anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3044236A2 (de) 2013-09-12 2016-07-20 Halozyme, Inc. Modifizierte anti-egfr-antikörper und verfahren zur verwendung davon
US10406167B2 (en) 2014-06-11 2019-09-10 Board Of Regents, The University Of Texas System Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10335608B2 (en) 2016-04-20 2019-07-02 Theralase Technologies, Inc. Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
CN108586469B (zh) * 2018-03-19 2021-05-07 西北师范大学 一种抑制硫化镉光腐蚀的方法
CN116264824A (zh) 2020-08-14 2023-06-16 德克萨斯大学系统董事会 用于锰化学疗法、光声成像和光热疗法的德克萨卟啉衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2308252A1 (de) * 1973-02-20 1974-08-22 Basf Ag Verfahren zur herstellung von mesotetraarylporphinen
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
US4977177A (en) * 1985-04-30 1990-12-11 Nippon Petrochemicals Company, Ltd. Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
CA1315780C (en) * 1986-01-17 1993-04-06 Yozo Fukuda Porphyrin derivatives
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4878891A (en) * 1987-06-25 1989-11-07 Baylor Research Foundation Method for eradicating infectious biological contaminants in body tissues
US5250668A (en) * 1988-01-11 1993-10-05 Morgan Alan R Production and use of porphyrin derivatives and of compositions containing such derivatives
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5256399A (en) * 1989-03-06 1993-10-26 Board Of Regents, The University Of Texas System Aromatic pentadentate expanded porphyrins in magnetic resonance imaging
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5272142A (en) * 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy

Also Published As

Publication number Publication date
NO942719D0 (no) 1994-07-20
PT623134E (pt) 2003-03-31
KR100286963B1 (ko) 2001-04-16
CA2127530A1 (en) 1993-07-22
DK0623134T3 (da) 2003-03-17
US5451576A (en) 1995-09-19
FI107157B (fi) 2001-06-15
US5504205A (en) 1996-04-02
NO301828B1 (no) 1997-12-15
FI943445A0 (fi) 1994-07-20
AU3436793A (en) 1993-08-03
WO1993014093A1 (en) 1993-07-22
ATE227291T1 (de) 2002-11-15
US5439570A (en) 1995-08-08
US5432171A (en) 1995-07-11
US5475104A (en) 1995-12-12
EP0623134A1 (de) 1994-11-09
US5733903A (en) 1998-03-31
AU664877B2 (en) 1995-12-07
NO942719L (no) 1994-09-19
US5994535A (en) 1999-11-30
US5252720A (en) 1993-10-12
ES2185627T3 (es) 2003-05-01
JP3530529B2 (ja) 2004-05-24
CA2127530C (en) 2001-05-29
JPH07503009A (ja) 1995-03-30
EP0623134B1 (de) 2002-11-06
NZ246795A (en) 1996-02-27
FI943445A (fi) 1994-07-20
US5569759A (en) 1996-10-29
DE69332469D1 (de) 2002-12-12

Similar Documents

Publication Publication Date Title
DE69332469T2 (de) Metallkomplexe von wasserlöslichen texaphyrinen
ES2020011A6 (es) Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
FI932032A0 (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
ATE366121T1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
ATE70449T1 (de) Zusammensetzungen von katecholischen butanen mit zink.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
BR9912327A (pt) Inibidores da uroquinase
MX9707022A (es) Derivados de fenilo trisustituidos.
NO20050640L (no) Rutenium anticancer komplekser
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
RU93047430A (ru) Состав на основе металлоорганических железосодержащих соединений, обладающий противоопухолевой активностью
ITMI920850A0 (it) Benzofurano-imidazoli per uso come inibitori di aromatisie 17,20-liasinella rpofilassi e trattamento del cancro della mammella e nell'iper- plasia prostatica benigna
UA9481A (uk) Засіб для профілактики і лікування вільнорадикального пошкодження органів і тканин

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee